Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Methylprednisolone (drug), hydrocortisone.
- Who it may be relevant to
- Registry conditions: Community Acquired Pneumonia (CAP). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Denmark
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The goal of this cluster randomized controlled trial is to determine the optimal treatment for community aquired pneumonia (CAP). The study compares the effects and side effects of hydrocortisone and prednisolone in patients above 18 years old diagnosed with severe CAP. The main question is whether there is a difference in all cause mortality within thirty days. Participants will be randomized to receive treatment with either hydrocortisone or prednisolone.
Interventions
- Drug Methylprednisolone (drug)
ATC code: H02AB06. Can be changed to Prednisolone 50 mg orally. - Drug hydrocortisone
ATC-code: H02AB09. Can be changed to 50 mg x 4 daily orally if appropriate.
Primary outcome measures
- All-cause mortality [Time frame: 30 days]
Secondary outcome measures (8)
- All-cause mortality [Time frame: 90 days]
- All-cause infections [Time frame: 90 days]
- Need for vasopressor treatment [Time frame: 30 days]
- Need for mechanical ventilation [Time frame: 30 days]
- Admission to ICU [Time frame: 30 days]
- Daily amount of insulin administered to the patient by day 7 or discharge from hospital [Time frame: 7 days]
- Gastrointestinal bleeding [Time frame: 30 days]
- Blood glucose levels [Time frame: 7 days]
Eligibility criteria
Inclusion criteria
- Age > 18 years
- Diagnosis of severe CAP for who the physician in charge decides for corticosteroid therapy for severe CAP.
Exclusion criteria
- Admitted >24 h
- Pregnant or breastfeeding women
- Active tuberculosis or fungal infection
- Pneumonia caused by influenza
- Intolerance to either study drug
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
Denmark · 14 centers
- Bornholm Hospital — Rønne
- Amager Hospital — Copenhagen
- Bispebjerg Hospital — Copenhagen
- Frederiksberg Hospital — Frederiksberg
- Gentofte Hospital — Hellerup
- Herlev Hospital — Herlev
- Hvidovre Hospital — Hvidovre
- Nordsjællands Hospital — Hillerød
- … and 6 more centers
Identifiers
NCT: NCT06892197 · MineraloCAP